Some critical considerations on the use of the nomifensine test in the hyperprolactinaemic syndrome.
Nomifensine has recently been proposed as a dynamic test to discriminate tumoral from functional hyperprolactinaemia. In the present study, this test was performed in 9 subjects with radiological signs of sellar alteration and in 6 with no signs of pituitary lesion. Adopting the criterion reported in the previous study, the test was considered positive in 2 subjects of the first group and in 2 subjects of the second group. Therefore, our study indicates that the ability of this test to discriminate subjects with tumorous or non-tumorous hyperprolactinaemia still appears debatable.
D000236:Adenoma / Q000175:diagnosis* / Q000000981:diagnostic imaging; D000293:Adolescent; D000328:Adult; D019411:Clinical Laboratory Techniques; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007546:Isoquinolines; D008297:Male; D008875:Middle Aged; D009627:Nomifensine; D010902:Pituitary Gland / Q000000981:diagnostic imaging; D010911:Pituitary Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging; D011388:Prolactin / Q000097:blood*; D011859:Radiography; D012016:Reference Values
D007546:Isoquinolines; D009627:Nomifensine; D011388:Prolactin